Aarti Drugs is a leading Indian pharmaceutical company engaged in the manufacturing of active pharmaceutical ingredients (APIs), intermediates, and specialty chemicals. They serve various therapeutic segments such as antibiotics, anti-protozoal, and anti-inflammatory. Their focus on quality and compliance has established them as a trusted supplier in both domestic and international markets.
PARAMETERS | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue (INR Cr) | 2507 -7.8% | 2720 5.2% | 2586 18.9% | 2174 16.7% | 1863 20.2% | 1550 19.3% | 1300 8.3% | 1200 4.8% | 1145 1.8% | 1125 16.3% | 967 14.1% | 848 27.8% | 663 27.6% | 520 9.2% | 476 27.4% | 374 - |
Net Operating Income (INR Cr) | 2529 -6.90% | 2716 9.14% | 2489 15.49% | 2155 19.31% | 1806 15.71% | 1561 25.51% | 1244 4.05% | 1195 4.85% | 1140 3.92% | 1097 0.00% | 972 17.68% | 826 25.25% | 659 32.80% | 501 4.71% | 479 25.23% | 382 22.33% |
Profit (INR Cr) | 171 3.1% | 166 -18.9% | 205 -26.9% | 280 98.3% | 141 57.6% | 90 9.0% | 82 0.6% | 82 19.0% | 69 -11.0% | 77 25.2% | 62 36.4% | 45 101.4% | 22 -5.6% | 24 -15.8% | 28 74.9% | 16 - |
Assets (INR Cr) | 1849 2.5% | 1805 13.0% | 1598 23.6% | 1293 20.3% | 1075 0.1% | 1074 4.2% | 1030 14.1% | 903 5.9% | 853 11.0% | 769 27.1% | 605 17.1% | 516 13.0% | 457 6.0% | 431 26.6% | 340 4.6% | 325 - |
Net Worth (INR Cr) | 1282 7.5% | 1192 15.1% | 1036 13.5% | 913 40.0% | 652 20.1% | 543 19.3% | 455 13.8% | 400 12.0% | 357 16.0% | 308 0.0% | 251 20.9% | 208 17.6% | 176 12.8% | 163 11.4% | 146 18.6% | 123 10.7% |
Employee Cost (INR Cr) | 91 12.6% | 80 16.1% | 69 5.2% | 66 7.4% | 61 12.5% | 55 4.6% | 52 8.7% | 48 19.3% | 40 20.8% | 33 16.7% | 29 10.2% | 26 11.1% | 23 16.8% | 20 34.9% | 15 23.2% | 12 - |
Interest Cost (INR Cr) | 38 | 37 | 24 | 26 | 37 | 44 | 38 | 40 | 48 | 42 | 37 | 31 | 25 | 17 | 19 | 26 |
Cash & Bank Balance (INR Cr) | 9 | 9 | 22 | 10 | 8 | 6 | 4 | 4 | 5 | 4 | 4 | 3 | 5 | 5 | 9 | 3 |
Total Debt (INR Cr) | 564 | 609 | 543 | 351 | 389 | 507 | 546 | 480 | 483 | 448 | 342 | 296 | 272 | 267 | 189 | 192 |
PARAMETERS | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Profit As % Of Revenues | 6.8% | 6.1% | 7.9% | 12.9% | 7.6% | 5.8% | 6.3% | 6.8% | 6.0% | 6.9% | 6.4% | 5.3% | 3.4% | 4.6% | 5.9% | 4.3% |
Profit As % Of Assets | 9.3% | 9.2% | 12.8% | 21.7% | 13.2% | 8.4% | 8.0% | 9.1% | 8.1% | 10.1% | 10.2% | 8.8% | 4.9% | 5.5% | 8.3% | 5.0% |
Profit As % Of Networth | 13.4% | 14.0% | 19.8% | 30.7% | 21.7% | 16.5% | 18.1% | 20.4% | 19.2% | 25.1% | 24.6% | 21.8% | 12.7% | 14.6% | 19.3% | 13.1% |
Interest Cost to EBITDA % | 11.8% | 12.0% | 7.2% | 6.0% | 14.1% | 20.6% | 19.0% | 21.0% | 26.7% | 24.5% | 24.8% | 25.1% | 32.2% | 24.8% | 22.6% | 39.8% |
Debt to Equity Ratio | 0.44 | 0.51 | 0.52 | 0.38 | 0.60 | 0.93 | 1.20 | 1.20 | 1.35 | 1.45 | 1.36 | 1.42 | 1.54 | 1.64 | 1.29 | 1.56 |
RONW | 13.9% | 14.9% | 21.0% | 35.8% | 23.7% | 18.0% | 19.2% | 21.6% | 20.7% | 25.1% | 26.9% | 23.6% | 13.5% | 15.0% | 20.0% | 14.4% |
ROCE | 15.0% | 15.4% | 20.3% | 33.4% | 20.7% | 16.6% | 16.9% | 17.8% | 17.7% | 19.3% | 21.9% | 19.9% | 13.7% | 13.0% | 19.9% | 16.1% |